Summary of the effects of all available interventions compared to standard care

The information presented in the figure below comes from a living network meta-analysis that combines all the available evidence on drug therapies for COVID-19. This statistical approach allows us to obtain estimates of effect for all potential comparisons, even those that have not been compared head-to-head in trials. We present the most trustworthy estimates of absolute effect for all available drug therapies for COVID-19 versus standard care. The colours distinguish between the most beneficial and harmful interventions compared to standard care, while the shading of cells indicates the certainty of the evidence of a particular drug based on the GRADE approach.

High/ moderate certainty

Low certainty

Very low certainty

No Evidence

Among the most
beneficial

Intermediate
benefit

Not convincingly
different
than standard care

Intermediate
harm

Among the most
harmful

Baseline risk tooltip
Minimal important difference tooltip
Laboratory confirmed SARS-CoV-2 infection
Suspected, probable, or laboratory confirmed confirmed SARS-CoV-2 infection
Admission to hospital tooltip
Mortality tooltip
Adverse effects leading to discontinuation tooltip
Time to symptom resolution or clinical improvement
Baseline risk
65 per 1,000
77 per 1,000
3 per 1,000
0 per 1,000
22 per 1,000
---
Minimal important difference
20 per 1,000
30 per 1,000
10 per 1,000
1 per 1,000
20 per 1,000
1 day
ARGOVIT AgNPs
bamlanivimab
casirivimab, imdevimab
cilgavimab, tixagevimab
dimethyl sulfoxide nasal spray
hydroxychloroquine
hydroxychloroquine, tenofovir disoproxil fumarate/emtricitabine
iota-carrageenan
iota-carrageenan, ivermectin
ivermectin
lopinavir-ritonavir
melatonin
povidone-iodine
tenofovir disoproxil fumarate/emtricitabine
vitamin C
vitamin C, zinc
Laboratory confirmed SARS-CoV-2 infection Suspected, probable, or laboratory confirmed confirmed SARS-CoV-2 infection Admission to hospital**** Mortality**** Adverse effects leading to discontinuation**** Time to symptom resolution or clinical improvement
-63 (-66 to -54)
0 (-17 to 17)
-24 (-50 to 24)
-2 (-34 to 30)
-53 (-62 to -40)
-72 (-78 to -59)
-3 (-34 to 28)
0 (-22 to 21)
0 (-2 to 1)
-48 (-62 to -17)
-4 (-35 to 27)
-1 (-30 to 28)
-57 (-67 to -21)
-2 (-18 to 19) tooltip
-10 (-28 to 10)
-2 (-6 to 2) tooltip
0 (-3 to 2) tooltip
6 (2 to 10)
-25 (-52 to 26)
-5 (-34 to 24)
34 (-13 to 81)
-51 (-65 to -9)
0 (-32 to 32)
0 (-30 to 30)
-5 (-27 to 17)
-56 (-65 to -36)
0 (-17 to 17)
54 (-22 to 173)
-74 (-77 to -68)
-3 (-36 to 30)
-2 (-25 to 21)
-12 (-55 to 90)
-2 (-34 to 30)
95 (-30 to 363)
0 (-33 to 33)
-6 (-45 to 62)
-3 (-36 to 30)
-2 (-31 to 27)
20 (6 to 33)
-5 (-44 to 62)
-5 (-34 to 23)
46 (-2 to 94)
82 (-10 to 220)
-3 (-36 to 30)
-1 (-31 to 27)
46 (27 to 65)
-3 (-44 to 67)
-3 (-36 to 30)
-1 (-31 to 27)
69 (47 to 90)